Focus: Salix is a specialty pharmaceutical company focused on gastroenterological and neurological small molecules, headquartered in Bridgewater, NJ. The company derives 83% of revenue from TRULANCE (plecanatide), a peak-lifecycle GI therapeutic.
Profile data last refreshed 6h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Salix Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Salix Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Salix Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Anchor product representing 83% of company revenue; guanylate cyclase activator with 10+ year exclusivity runway.
PPI combination nearing loss of exclusivity; secondary revenue contributor in critical-care setting.
Bowel prep formulation with 9+ year exclusivity; smaller revenue base in competitive endoscopy market.
5-ASA therapy for inflammatory bowel disease; patent cliff in 2030 represents first major revenue cliff for the company.
Corticosteroid for IBD; second-line therapy in GI inflammation portfolio with 2031 LOE exposure.
Peripherally-acting mu-opioid antagonist; complement to TRULANCE in OIC market with 2031 exclusivity cliff.
PPAR-α agonist fibrate for lipid management; mature asset with approaching loss of exclusivity and minimal revenue tracking.
4 discontinued, 1 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo